

The Configuration of Biomolecular Markers in Cancer of the Uterine Cervix. Personalized Therapy. Monitoring and Prognosis

V.M. Prunoiu¹, M.A. Marincaș¹, C. Cirimbei¹, S. Ionescu¹, S. Zurac², M. Radu¹, R. Nicolaescu¹, E. Brătucu¹, N.D. Straja¹

¹Ist Clinic of General Surgery and Surgical Oncology, IIInd Clinic of Surgical Oncology, Pathology Department, "Al. Trestioreanu" Oncology Institute, Bucharest, Romania

²Pathology Department, Colentina Clinical Hospital, Bucharest, Romania

Abstract

Introduction: The paper deals with the diagnosis of some aggressive forms of uterine cervix cancers, resistant to radio/ chemotherapy, using biomolecular markers. For this study, the destruction of tumours in stages II-IIIb carried out by hyperthermia induced by different sources of energy. The aimed targets are to embed a quick and simple technique of haemostasis used in bleeding uterine cervix tumours associated with acute anaemia in the treatment protocols and to identify biomolecular criteria revealing tumour aggressiveness and treatment response.

Method: The proposed method consists in radiofrequency ablation (RFA) applied to uterine cervix bleeding tumours with acute secondary anaemia. Studying 16 patients displaying aggressive cancer forms resistant to radio/chemotherapy treated by the abovementioned method, we assessed that the commonly present markers: Ki67, p53 and Bcl-2, may be a substantial indication of such cases. Aggressiveness and treatment resistance was defined based on clinical and paraclinical investigations.

Results: RFA haemostasis achieved in approximately 20 min proved the efficiency of this method. A secondary important effect was local tumour volume decrease, resulting in the improvement of radio-chemotherapy responsiveness.

Conclusions: Once an aggressive and radio-chemotherapy resistant cancer is diagnosed, the quantitative, qualitative and associative presence of the biomolecular markers mentioned hereinbefore, could influence the personalised treatment attitude (radiofrequency, neoadjuvant chemotherapy), which on the long term, may increase patient survival and life quality improvement.

Key words: biomolecular markers Ki67, p53 and Bcl-2, tumour of the uterine cervix, hyperthermia

Corresponding author: Dr. Virgiliu Mihail Prunoiu
„Al. Trestioreanu” Oncology Institute
Ist Clinic of General Surgery and Surgical Oncology
252 Șoseaua Fundeni, Bucharest, 22328
E-mail: virgiliuprunoiu@yahoo.com